

**Virtual Annual Scientific Meeting of the American Headache Society
Preliminary Program**

**schedule subject to change*

<u>June 2020</u>
<p>Opening Remarks Peter J. Goadsby, MD, PhD, FAHS President</p>
<p>Headache Medicine in the Era of COVID-19</p>
<p>Headache & COVID-19: A Short-term Challenge with Long-term Insights</p> <p>Patricia Pozo Rosich, MD, PhD Vall d'Hebron Hospital Barcelona, Spain</p>
<p>COVID-19 and Headache: the New York Experience</p> <p>Matthew S. Robbins, MD, FAHS Weill Cornell Medicine New York, New York</p>
<p>Migraine Care in the Era of COVID-19: Clinical Pearls and Plea to Insurers</p> <p>Christina L. Szperka, MD, MSCE, FAHS Perelman School of Medicine at the University of Pennsylvania, Children's Hospital of Philadelphia Philadelphia, Pennsylvania</p>
<p>Award Presentations</p>
<p>Harold G. Wolff Award Lecture</p> <p>Cognitive Networks Disarrangement in Patients with Migraine Predicts Cutaneous Allodynia</p> <p>Antonio Russo, MD, PhD University of Campania "Luigi Vanvitelli" Carinaro, Campania, Italy</p>

Early Career Award Lecture

Alterations in Functional Connectivity during Different Phases of the Triggered Migraine Attack

Nazia Karsan, MBBS, PhD
King's College London
London, United Kingdom

Seymour Solomon Award Lecture

Observations 2020 - 'Teaching Headache'

R. Allan Purdy, MD, FAHS
Dalhousie University
Halifax, Nova Scotia

John R. Graham Award Lecture

Practical Approach to Eye Pain and Photophobia

Kathleen B. Digre, MD, FAHS
University of Utah
Salt Lake City, Utah

Frontiers in Headache Research Award Virtual Platform Presentations

Exploring Naturally Occurring Clinical Subgroups of Post-traumatic Headache

Tommy Chan, MD
Stanford University
Palo Alto, California

Efficacy and Tolerability of CGRP Monoclonal Antibody Medications in Patients with Chronic Migraine Undergoing Treatment with OnabotulinumtoxinA

Fred Cohen, MD
Montefiore Medical Center
Great Neck, New York

Identify Biomarkers in Migraine and Cluster Headache by Improving Experimental Design

Simona Denise Frederiksen, PhD, MS
University of Calgary, Cumming School of Medicine
Calgary, Alberta

<p>Improving Headache Management in the Pediatric Emergency Department</p> <p>Jessica Hauser, MD, PhD University of Washington, Seattle Children's Hospital Seattle, Washington</p>
<p>Trainee Headache and Education Management (THEME) Study</p> <p>Candice Todd-Aziz, MD University of Toronto Toronto, Ontario</p>
<p>Endogenous Analgesia in Patients with Chronic Migraine: A Study of Conditioned Pain Modulation</p> <p>Hsiangkuo Yuan, MD, PhD Thomas Jefferson University Philadelphia, Pennsylvania</p>
<p>Frontiers in Headache Research Award Virtual Poster Presentations</p>
<p>Real World Efficacy, Tolerability and Safety Study of Ubrogepant, Rimegepant, and Lasmiditan</p> <p>Chia-Chun Chiang, MD Mayo Clinic Arizona Scottsdale, Arizona</p>
<p>Development of a Visualization Tool for Tracking Modifiable Risk Factors for Progression from Episodic to Chronic Migraine</p> <p>Ami Cuneo, MD University of Washington Seattle, Washington</p>
<p>Retrospective Review of the Use of Anti-CGRP Monoclonal Antibodies to Treat Headaches in Patients with Idiopathic Intracranial Hypertension</p> <p>Lindsay Frerichs, MD UT Southwestern Dallas, Texas</p>
<p>Real-World Experience with Calcitonin Gene-related Peptide (CGRP) Antagonists in the Treatment of Migraine</p> <p>Payal Patel Soni, MD Cleveland Clinic</p>

Cleveland, Ohio
A Real-World Comparison of Erenumab and Galcanezumab in a Tertiary Headache Center Alise Pham, DO Brigham and Women's Hospital, Harvard Medical School Boston, Massachusetts
5th Annual Migraine Moment Short Film Contest
Abstract Virtual Platform Presentations
Childhood and Adolescent Migraine Prevention [CHAMP] Trial: The 3-year Follow-up Survey Results
Effects of Pre-Injury Migraine Frequency on Post-Traumatic Headache Recovery in the General Adult Population: The Toronto Concussion Study
Exploring the Boundaries Between Episodic and Chronic Migraine: Results from the CaMEO Study
Identifying Barriers to Care-seeking, Diagnosis, and Preventive Medication Among Those with Migraine: Results of the OVERCOME Study
Inter and Intra-individual Differences in the Association Between Menstruation and Migraine
Migraine as a Risk Factor for Dementia: A National Register-based Follow-up Study
Mild Traumatic Brain Injury Induces Long-lasting Sensitization to Pain in Mice
Prevalence of Headache and Comorbidities among Men and Women Veterans across the Veterans Health Administration – a 10-year Cohort Study
Role of PAR-2 Receptors in Migraine Using a Novel, Translatable Injury-Free Preclinical Model
Survivors of Military Sexual Trauma Face Increased risk of Migraine Headaches and Worse Headache Care
The Impact of Migraine on Pregnancy Plan: Insights from the American Registry for Migraine Research (ARMR)
The Role of Cerebellar CGRP in Migraine-like Behavior

Industry Abstract Virtual Platform Presentations
Characteristics of Individuals with Migraine Who are Eligible for Novel CGRP Monoclonal Antibodies: Results of the OVERCOME Study
Consistency of the Efficacy of Single-use and Repeated-use of M207 (intracutaneous microneedle zolmitriptan) for the Acute Treatment of Migraine; Results for Pain Freedom, Pain Relief, and Sustained Pain Freedom and Pain Relief
DFN-15 (Celecoxib Oral Solution, 25 mg/mL) in the Acute Treatment of Episodic Migraine: Efficacy Results from Two Phase III Randomized, Double-blind, Placebo-controlled Studies
Efficacy and Safety of AXS-07 (MoSEIC™ Meloxicam/Rizatriptan) in the Acute Treatment of Migraine: Results from the MOMENTUM Phase 3 Trial
Eptinezumab Demonstrated Migraine Preventive Efficacy on Day 1 After Dosing: Closed Testing Analysis from PROMISE-1 and PROMISE-2
Improved Functionality, Satisfaction, and Global Impression of Change with Ubrogepant for the Acute Treatment of Migraine in Triptan Insufficient Responders
Multiple, Once-Daily, Oral Doses of 170 mg Atogepant for 28 Days Are Safe and Well Tolerated with No Clinically Significant Effect on Alanine Aminotransferase in Healthy Adults
Multiple-ascending Dose, Safety, Tolerability, Pharmacokinetic, and Drug-Drug Interaction Study with Lasmiditan
Pooled Analysis of Cardiovascular Safety with Fremanezumab Treatment in Patients With Migraine by Number of Cardiovascular or Cerebrovascular Risk Factors
Pregnancy Outcomes Following Exposure to OnabotulinumtoxinA Update – 29 Years of Safety Observation
Rimegepant 75 mg Provides Early and Sustained Relief of Migraine with a Single Oral Dose: Results from 3 Phase 3 Clinical Trials
Sustained Efficacy and Safety of Erenumab in Patients with Episodic Migraine who Failed 2–4 Prior Preventive Treatments: 2-year Interim Results of the LIBERTY Open-label Extension Study
Virtual Abstract Poster Presentations by Category
Basic Science
Calcitonin Gene-related Peptide Facilitates Sensitization of Vestibular Nuclear Neurons in a Rat Model of Chronic Migraine

Dietary Supplementation with Grape Seed Extract Inhibits Trigeminal Nociception Via a Serotonergic/GABAergic Mechanism
Perivascular CGRP Actions in a Mouse Model of Migraine
Chronic Migraine
A Real World Comparison of Erenumab and Galcanezumab in a Tertiary Headache Center
A Real-World Perspective of Patients With Episodic Migraine or Chronic Migraine Prescribed AJOVY in the United States
Calcitonin Gene Related Peptide Monoclonal Antibodies in the treatment of migraine: Is there a difference in efficacy between inhibitors of the ligand compared to inhibitors of the receptor?
Cervicogenic Headache Responsive to Galcanezumab in Patients with Comorbid Migraine: A Case Series
CGRP Monoclonal Adverse Effects: Evaluation Via Use of a Checklist
CGRP Monoclonal Antibodies in the Treatment of Migraine in Elderly Patients: A Single Center Experience
CGRP Monoclonals: Efficacy, Side Effects, and Switching
Clinically Meaningful Responses to Fremanezumab in Patients With Migraine and Inadequate Response to 2–4 Classes of Migraine Preventive Medication: Results of the Open-label Period of the Phase 3b FOCUS Study
Combination of Erenumab (Aimovig) and Onabotulinum Toxin A (BoNT-A or Botox) is Safe and Effective
Consecutive Headache-Free Days After Long-term Treatment With OnabotulinumtoxinA in Patients With Chronic Migraine: A Post Hoc Analysis of the Pooled PREEMPT Studies
Depression and Migraine – a Double Whammy on Patient-reported Health
Disability Severity Category Shift with Fremanezumab Treatment: Pooled Results of 3 Randomized, Double-blind, Placebo-controlled Phase 3 Studies
Effect of Fremanezumab on Depression Status in Patients With Episodic and Chronic Migraine and Documented Inadequate Response to 2-4 Classes of Migraine Preventive Medications During the Open-label Period of the Phase 3b FOCUS Study

Efficacy and Safety of Fremanezumab in Patients With Episodic and Chronic Migraine and Inadequate Response to 2-4 Classes of Preventive Medications: Results of the Open-label Period of the Phase 3b FOCUS Study
Efficacy and Tolerability of CGRP Monoclonal Antibody Medications in Patients with Chronic Migraine Undergoing Treatment with OnabotulinumtoxinA
Efficacy of Fremanezumab by Prior Number of Preventive Treatments With Inadequate Response in Patients With Episodic Migraine and Chronic Migraine: Results of the International, Multicenter Phase 3b FOCUS Study
Efficacy of Fremanezumab in Male Patients With Migraine and Documented Inadequate Response to 2-4 Classes of Migraine Preventive Treatments: Results of the Randomized, Placebo-controlled FOCUS Study
Efficacy of Fremanezumab Treatment in Patients ≥ 60 Years of Age With Episodic or Chronic Migraine: Pooled Results of 3 Randomized, Double-blind, Placebo-controlled Phase 3 Studies Efficacy of Inpatient Infusions for Patients with Chronic Migraine and History of Head Trauma
Experiences of an Academic Headache Center with Serial Sphenopalatine Blocks to Treat Chronic Migraine
Headache Treatment Outcomes Following Conversion from Botox to Dysport
Healthcare Resource Utilization and Health-Related Quality of Life in Adult Patients With Chronic Migraine: Results From the PREDICT Study
Health-Related Quality of Life Outcomes With Fremanezumab in Patients With Episodic and Chronic Migraine and Documented Inadequate Response to 2-4 Classes of Migraine Preventive Medications: Open-label Extension of the FOCUS Study
Impact of Fremanezumab on Disability in Migraine Patients With Medication Overuse and Documented Inadequate Response to 2-4 Classes of Preventive Treatments: Subgroup Analysis of the FOCUS Study
Impact of Fremanezumab on Disability Severity According to the AHS Consensus: Pooled Results of 3 Randomized, Double-blind, Placebo-controlled Phase 3 Studies
Impact of Fremanezumab on Headache-related Disability in Patients With Migraine and Inadequate Response to 2-4 Classes of Preventive

Medication: Results of the Open-label Extension of the Phase 3b FOCUS Study
Impact of Fremanezumab on Migraine-associated Symptoms in Patients With Migraine Who Failed 2-4 Classes of Preventive Medications: Results of the Open-label Period of the Phase 3b FOCUS Study
Impact of Fremanezumab on Migraine-specific Quality of Life in Patients With Medication Overuse and Documented Inadequate Response to 2-4 Migraine Preventive Medication Classes in the FOCUS Study
Improvements in Headache-related Disability With Fremanezumab in Patients ≥ 60 Years of Age With Migraine: Pooled Results of 3 Randomized, Double-blind, Placebo-controlled Phase 3 Studies
Improvements in Quality-of-Life, Productivity, and Satisfaction With Fremanezumab in Migraine Patients ≥ 60 Years of Age: Pooled Results of 3 Randomized, Double-blind, Placebo-controlled Phase 3 Studies
Migraine Attack Probability is Modulated by Oxytocin Receptor Activity on Trigeminal Neurons
Migraine Exacerbation After Intra-abdominal Migration of a Levonorgestrel-releasing IUD: A Case Report
Modifications to the PREEMPT Protocol for OnabotulinumtoxinA Injections for Chronic migraine in Clinical Practice
Patient Satisfaction With Fremanezumab During the Open-label Period of the Phase 3b FOCUS Study in Patients With Episodic and Chronic Migraine and Documented Inadequate Response to 2-4 Classes of Migraine Preventive Medications
Pooled Analysis of Cardiovascular Safety With Fremanezumab Treatment in Patients With Migraine and Concomitant Triptan Use
Pooled Analysis of Tolerability With Fremanezumab Treatment in Patients With Episodic or Chronic Migraine and Cardiovascular Medication Use at Baseline
Profiling Physicians Prescribing Concurrent Anti-Calcitonin Gene-Related Peptide Monoclonal Antibody and OnabotulinumtoxinA for Migraine Prevention: Results from an Annual US Patient Chart Audit
Safety of Dihydroergotamine for Acute Migraine Treatment: Reality vs Perception
Safety of Using OnabotulinumtoxinA for the Treatment of Chronic Migraine in Pregnancy

Super-Responders and Non-Responders to CGRP Monoclonal Antibodies in the Treatment of Migraine
Sustained Clinical Benefits Following OnabotulinumtoxinA Treatment in Patients With Chronic Migraine: A Post Hoc Analysis of the Pooled PREEMPT Studies
The Efficacy of Dihydroergotamine Versus Emerging Acute Migraine Medications
The Impact of Hypnotic Use on Cognitive Function in Migraine Patients
Transient Facial Nerve Paralysis Following Injection of OnabotulinumtoxinA for Chronic Migraine
Treatment Patterns and Characteristics of Patients Prescribed AJOVY, Emgality, or Aimovig
Trending the First Two Years of Anti-Calcitonin Gene-Related Peptide Class Availability for Migraine Prevention: Results from an Independent Quarterly US Survey of Neurologists and Migraine Specialists
Work Productivity and Activity Impairment Outcomes With Fremanezumab in Patients With Migraine and Inadequate Response to 2-4 Migraine Preventive Medication Classes: Open-label Extension of FOCUS Study
Clinical Studies
A Novel Technique for Sphenopalatine Ganglion Block without Use of Catheter
A Retrospective Cohort Study of Urgent Care Visits and Revisits for Headache and Migraine
A Single Supratherapeutic Dose of Atogepant Does Not Affect Cardiac Repolarization in Healthy Adults
Alterations in Functional Connectivity During Different Phases of the Triggered Migraine Attack
Are People with Migraine Willing to Engage in Digitally Based Behavioral Therapies: A look at Recruitment Statistics for a Mobile Health Study
Blood-CSF Barrier Transport in Migraine Differs with Headache Frequency
Coadministration of Single Therapeutic Oral Doses of Atogepant and Sumatriptan Produces No Clinically Relevant Drug-Drug Interactions

Effect of a Cervical Exercise Protocol for Patients with Migraine on Craniocervical Flexion Test and Migraine and Neck Related Disabilities
Episodic Status Migrainosus: First Mexican Series
Erenumab Response in Highly Refractory Migraine Patients Followed at a Canadian Tertiary Headache Clinic: Preliminary Results of a Small Case Series at Six Months
Follow the Money: Professional Subjects in Migraine Studies
WITHDRAWN BY AUTHOR Headache Relief Should Only be Evaluated After 2 hours and Used as a Historical Control. Pain-free Should be used as Primary Outcome After 2 hours and as Secondary Parameter at Other Time points in Trials Treating Acute Migraine Attacks
Hypothyroidism as Comorbidity of Chronic Headaches: PREMECEF Results
Increased Headache Prevalence in Patients with Chronic Peripheral Neuropathic Pain
Interictal Burden Attributed to Migraine: An Analysis from the American Registry for Migraine Research (ARMR)
Interim Results of a Phase 1 Single Ascending Dose Study of XC101-D13H, a Novel Compound for the Prevention of Migraine
Levetiracetam in Management of Bilateral Trigeminal Neuralgia due to Large Glomus Tumor
Measuring Headache Impact: Combining Pain and Disability Scores to Provide a Single Measure of Overall Headache Severity and Frequency
Medical Marijuana in the Management of Headache Disorders
Migraine with Aura in Mexico: Results from PREMECEF
Migraine Without Aura in Mexico: Results from PREMECEF 2020
Pattern and Frequency of Headache Types in Patients with Systemic Lupus Erythematosus
Pericranial Nerve Block in Patients with Headache Difficult to Treat: An Option in a Emergent Country
Pharmacokinetics and Safety of Single-Dose Atogepant in Participants With Hepatic Impairment

Potential Clinical Evidence for Limbic System Sensitization in Migraine
Preliminary Analysis of the Sustained Effects of a Single Low Oral Dose of Psilocybin in Migraine Headache
Riboflavin for Migraine Prevention in Children and Adolescents: A Retrospective Review
Single Therapeutic Doses of Atogepant Are Not Associated With a Clinically Relevant Drug-Drug Interaction When Coadministered With Acetaminophen or Naproxen
Smartphone Delivered Progressive Muscle Relaxation (RELAXaHEAD) for the Treatment of Migraine in Primary Care: A Pilot Randomized Controlled Study
Surveying the Patient Perspective on Headache Intake Forms: A Cohort Study
The Migraine Disability Assessment as an Indicator of Resilience in Patients with Headaches
The Relationship Between Cranial Autonomic Symptoms and Central Nervous Sensitization in Migraine Patients Using the Central Sensitization Inventory
Utilization of Smartphone Based Migraine Tracking with a Free Text Feature: A Retrospective Analysis
Cluster Headache and other Trigeminal Autonomic Cephalalgias
Atypical Trigeminal Autonomic Cephalalgia Resembling Hemicrania Continua Improved with Trigeminal Microvascular Decompression: A Case Report
Bilateral Hemicrania Continua Presenting as New Daily Persistent Headache Responsive to Indomethacin
Chronic Cluster-like Headache Secondary to Thalamic Cavernoma with Subsequent Intracranial Hemorrhage
Clinical Evidence for Peripheral and Central Nervous System Sensitization in Hemicrania Continua
Clinical Profile of Chronic Cluster Headache in a Regional Headache Center in Japan

Distinguishing Clinical Features Between Hemicrania Continua and High Frequency Chronic Migraine
Efficacy of Galcanezumab in Patients With Episodic Cluster Headaches and a History of Preventive Treatment Failure
Evaluation of the Computerized Headache Screening Tool (CHAT-III) for the Diagnosis of Cluster Headache
Numb Chin Syndrome and Cluster Headache like as first manifestation of high-grade B-Cell Lymphoma
Review of the World's Largest Active Hemicrania Continua Cohort: Emergence of New Clinical and Treatment Insights
Sphenopalatine Ganglion Block for the treatment of SUNCT Syndrome in a Geriatric Patient
The Impact of Remission and Coexisting Migraine on Anxiety and Depression in Cluster Headache
Two Novel Cases of Secondary Hemicrania Continua
Epidemiology, Pharmacoeconomics, and Outcomes Research of Headache
A Design Framework for the Creation of a User-centered Headache Diary App Through a Qualitative Analysis of App Reviews
Acute Migraine Medication and Medication Overuse Headache: A Systematic Literature Review
Acute Treatment Management Gaps in People with Migraine: Results of the CaMEO Study
An Analysis of Electronic Tasks and Messages Generated by a Headache Clinic Population
Assessing Barriers to Care in Episodic and Chronic Migraine: Results From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study
Association and Effect of Sociodemographics on the Severity and Risk of Mortality in Hospital Admissions for Headache
Budget Impact of Lasmiditan for the Acute Treatment of Migraine in the United States
Comorbidity in Migraine Patients of a Referral Centre from Mexico City

Comorbidity, Treatment Patterns and Economic Burden of Primary Headache Disorders: An Administrative Claims Data Analysis
Comparative Efficacy and Safety of Rimegepant Versus Ubrogapant and Lasmiditan for Acute Treatment of Migraine: A Network Meta-analysis (NMA)
Comparing Complementary and Integrative Health Perspectives among VA Providers and Veteran Patients for the Treatment of Headache Disorders
Electronic Health Record Documentation of Headache Presentation: Argument for Improvement in an Integrated Healthcare System in Order to Better Treatment
Evaluating the Effects of Probiotics on Adults with Migraine and Comorbid Gastrointestinal Disorders: A Systematic Review
Examining the Utilization of Neurotoxins in the Treatment of Chronic Migraine – A Cohort Study from the Veterans Health Administration
Factors Associated with Frequency of In-Between Visit Remote Communications in Patients with Headache at an Academic Medical Center
Gastrointestinal Comorbidities Representing a Relative Contraindication to NSAID Use: Results From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study
Harnessing the Electronic Health Record to Improve Headache Care
Headache Not Otherwise Specified: Impact of the Transition from ICD-9 to ICD-10 Diagnostic Classification within the Veterans Health Administration
Higher Prevalence of Butalbital Use in Pregnant Patients with Headache
Impact and Burden of Episodic, Acute Migraine: A Patient Experience Study
Improving Headache Diagnosis and Treatment through Patient Headache Questionnaires
Inter-disciplinary Influences in Headache Literature: a Network Citation Analysis of PubMed Central Articles
Lost Time is Associated with Total Health Care and Pharmaceutical Costs – A US-Based Real World Longitudinal Analysis

Matching-adjusted Indirect Comparisons of Intermittent Oral Rimegepant Versus Placebo and Injectable anti-CGRP Monoclonal Antibodies (mAb) Examining Health-related Quality of Life (HRQoL)
Matching-adjusted Indirect Comparisons of Intermittent Oral Rimegepant Versus Placebo and Injectable anti-CGRP-targeted Monoclonal Antibodies Examining Monthly Migraine Days in the Treatment of Migraine
MIDAS Disability Grades are Associated with Total Health Care and Pharmaceutical Costs – A US-Based Real World Longitudinal Analysis
Migraine Patients Exhibit Increased Relative Risk For Medication Overuse Headache (MOH) With Sustained Triptan Treatment – Results From a Large Scale Real-World Claims Analysis
Migraine Patients Exhibit Increased Relative Risk for Opioid Dependence With Sustained Triptan Treatment – Results From a Large Scale Real-World Claims Analysis
MSQ Utility Mapping of Rimegepant by Change in Monthly Migraine Days
Observations on the Landscape of Migraine Social Media: a Twitter Longitudinal Infodemiology Study
Operationalization of Triptan Labels to Identify Migraine Patients with Cardiovascular Contraindications and Warnings Using Real-World Claims Data
Persistence to OnabotulinumtoxinA Versus Calcitonin Gene-related Peptide Monoclonal Antibodies (CGRP mAbs) Among Migraine Patients in a US Electronic Health Record Database
Poor Sleep Quality, Stress and Depressive Symptoms and Subsequent Headache in Patients with Episodic Migraine: A Prospective Cohort Study
Prevalence and Impact of Cutaneous Allodynia in Migraine, Probable Migraine and Tension-type Headache: A Population-based Study in Korea
Quickest Way to 50% Less Headache Days: An Operational Research Model and Its Implementation for Chronic Migraine
Real-World Persistence in Patients Treated with OnabotulinumtoxinA or Calcitonin Gene-Related Peptide Monoclonal Antibodies (CGRP mAbs) for Migraine: A Large US Administrative Claims Database Study
Switching and Discontinuation Patterns Among Triptan Users: A Systematic Literature Review

The Association between Adverse Childhood Experiences and Primary Headache Disorders: A Prognostic Systematic Review and Meta-Analysis
The Effect of Nerve Blocks on Head Pain with or without Opioid Use
Tracking Migraines with @MigraineTweets: Near Real-time Epidemiology in the Era of Twitter?
Headache Disorders in Children and Adolescents
A Case of Aseptic Meningitis from Enterovirus Causing Elevated Intracranial Pressure
Clinical Characteristics of Pediatric Patients with New Daily Persistent Headache Presenting at a Multidisciplinary Headache Program
Correlation of Pediatric Headache-related Functional Disability Inventory (FDI) and Prolonged School Absence
Development of a Text Message-based Headache Diary in Adolescents and Children
Endogenous Modulation and Central Sensitization in New Daily Persistent Headache in Children: Preliminary Findings
Erenumab Use in Refractory Adolescent Headache Disorders
Establishing a National Real-World Data Pediatric Migraine Registry: Proof of Principle
Impact of School Placement on Pediatric Patients with Migraine
Longitudinal Impact of Parental and Family Factors in Adolescents with Migraine and Tension-Type Headache: A Prospective Study
Pure Ictal Epileptic Headache in Children
Red Ear Syndrome, a Case Report of a Teenager and Review of Literature from 1996 to 2019
Safety and Effectiveness of Onabotulinum Toxin A for Chronic Migraine in Children & Adolescents: A Retrospective Cohort Study
Safety and Efficacy of Short Duration Lidocaine Infusion for Pediatric/Adolescent Patients with NDPH
The Unexpected Effect of Botox for Chronic Migraine Protocol on Adolescents with Self-injurious Behavior and Chronic Head Pain

Topiramate is Helpful for Migraine Prevention in Adolescents: A Pediatric Headache Clinic's Experience
Headache Medicine Education
A 25-year Gender Trend Analysis of Authorship in Headache: The Journal of Head and Face Pain
Efficacy and Safety of Ubrogapant in Participants Taking Concomitant Preventive Medication
Responder Rates to OnabotulinumtoxinA in Patients With Chronic Migraine: A Post Hoc Analysis of the COMPEL Study
Ubrogapant for the Acute Treatment of Migraine: Pooled Efficacy From ACHIEVE I and ACHIEVE II Phase 3 Trials
Wearing Off in CGRP Fremanezumab-vfrm and Galcanezumab-gnlm
Industry-initiated Clinical Trials
A Close Association of Pain Freedom with Freedom from Most Bothersome Symptom and from Migraine-related Functional Disability in Lasmiditan Studies SAMURAI and SPARTAN
Acute Treatment of Migraine with Oral Rimegepant 75 mg Improves Health Related Quality of Life: Results from a Long-Term, Open-Label Safety Study (BHV3000-201)
Acute Treatment of Migraine with Rimegepant 75mg Confers Robust Improvement in Absenteeism, Presenteeism and Productivity: Results from a One Year, Open-Label, Safety Study (BHV3000-201)
Acute Treatment with Oral Rimegepant 75mg Reduces Migraine-Related Disability: Results from a One Year, Open-Label Safety Study (BHV3000-201)
Analysis of Initial Non-Response to Galcanezumab in Patients with Treatment-Resistant Migraine: Results from the CONQUER Trial
Benefit of Migraine Prevention with Erenumab in Patients Receiving Background Standard-of-Care Acute Treatment
Benefits of Long-Term OnabotulinumtoxinA Treatment in Chronic Migraine: Results from the COMPEL Study
Cardiovascular Safety of Erenumab in Patients with Migraine and Aura
Consistency of Effect with Galcanezumab Across Multiple Cluster Periods in Episodic Cluster Headache

Early Onset of Efficacy Following Galcanezumab Treatment in Patients with Previous Preventive Failures
Effect of a Change in Lasmiditan Dose on Drug Efficacy and Safety: Phase 3 Study Findings
Effect of Erenumab on Monthly Migraine Days and Monthly Migraine Attacks in Patients with Episodic Migraine
Effects of Erenumab on Patient-reported Outcomes in a Subgroup of Patients with Episodic Migraine and Severe Functional Impairment
Efficacy of Erenumab in Chronic Migraine (CM) Patients with Acute Headache Medication Overuse (MO): A Post-hoc Analysis Assessing Outcomes Using Different Definitions of Remission
Efficacy of Galcanezumab in Adults with Treatment Resistant Migraine and Concomitant Pain Disorders: Post-hoc Subpopulation Analyses from the Randomized, Double-Blind, Placebo-Controlled CONQUER Study
Efficacy of Galcanezumab in Patients Who had not Previously Benefited from Commonly Prescribed Migraine Preventive Treatments
Eptinezumab Improved Patient-Reported Outcomes in Patients with Chronic Migraine and Medication-Overuse Headache: Subgroup Analysis of PROMISE-2
Eptinezumab Reduced Acute Medication Use in Patients with Chronic Migraine and Medication-Overuse Headache: Subgroup Analysis of PROMISE-2
Eptinezumab Reduced the Frequency of Migraine Days in Patients with Chronic Migraine and Medication-Overuse Headache: Subgroup Analysis of PROMISE-2
Eptinezumab Treatment Reduced Acute Headache Medication Use with Corresponding Reduction in Migraine Frequency in Patients with Chronic Migraine and Medication-Overuse Headache in PROMISE-2
Impact of Galcanezumab on Total Pain Burden: Findings from Phase 3 Randomized, Double-Blind, Placebo-Controlled Studies in Patients with Episodic or Chronic Migraine
Impact of Galcanezumab on Total Pain Burden in Patients with Chronic Cluster Headache: Post-hoc Analysis from a Phase 3, Randomized, Double-blind, Placebo-controlled Study
Impact of Integrating an App into the Management of Patients with Migraine in the Primary Care Setting

Improvement in Function after Lasmiditan Treatment: Post-hoc Analysis of Pooled Data from Phase 3 Studies
Incidence of TEAEs By Dose in a Multicenter, Open-Label, Long-Term, Safety Study of DFN-02 (Tosymra™, Nasal Spray of Sumatriptan 10 mg Plus Permeation Enhancer Intravail®) for Acute Migraine Treatment
Long-term Cardiovascular Safety of Lasmiditan for the Acute Treatment of Migraine For Up to One Year: Interim Results of an Open-Label Phase 3 Study (GLADIATOR)
Long-Term Safety of Rimegepant 75 mg for the Acute Treatment of Migraine (Study 201)
Low Rates of Rescue Medication Usage in Subjects Treated with a Single Dose of Rimegepant 75 mg for the Acute Treatment of Migraine: Results from 3 Phase 3 Clinical Trials
Migraine Response in Patients with Migraine Receiving Eptinezumab Treatment: Consistency Throughout the PROMISE-1 and PROMISE-2 Trials
Migraine-Specific Quality of Life Questionnaire (MSQ) version 2.1 Score Improvement in Japanese Patients with Episodic Migraine by Galcanezumab Treatment: CGAN Japan Phase 2 Study
OnabotulinumtoxinA Treatment Improved Health-Related Quality of Life in Adults with Chronic Migraine: Results from a Prospective, Observational Study (PREDICT)
Oral Rimegepant 75 mg is Safe and Well Tolerated in Adults With Migraine and Cardiovascular Risk Factors: Results of a Multicenter, Long-Term, Open-Label Safety Study
Oral Rimegepant 75 mg is Well Tolerated When Used Concomitantly With Injectable Anti-CGRP Monoclonal Antibodies: Results From a Multicenter, Long-Term, Open-Label Safety Study
Oral Rimegepant Produces No Significant Effect on Blood Pressure When Administered Concomitantly with SC Sumatriptan
Patient Acceptability of a Novel Upper Nasal Delivery System for DHE – Using the Precision Olfactory Delivery Device
Patient Preference and Improved Clinical Global Impression of Change with Rimegepant 75 mg for the Acute Treatment of Migraine: Results from a Long-Term Open-Label Safety Study (Study 201)

Patient-Identified Most Bothersome Symptom in Patients with Chronic Migraine: An Analysis of PROMISE-2
Relative Contribution of Early-Onset Efficacy with Eptinezumab to Change in Headache-Related Life Impact in Patients with Chronic Migraine
Rimegepant 75 mg Is Associated with Significant Reductions in Monthly Migraine Days: Post-hoc Analyses of a Multicenter, Open Label Long-term Safety Study of Rimegepant for the Acute Treatment of Migraine
Rimegepant 75 mg is Safe and Well Tolerated for the Acute Treatment of Migraine in Adults Using Selective Serotonin Reuptake Inhibitors (SSRIs) and Other Antidepressants: Results from a Long-Term, Open-Label Safety Study (Study 201)
Rimegepant 75 mg is Safe and Well Tolerated for the Acute Treatment of Migraine in Adults With a History of Depression or Anxiety: Results from a Long-Term Open-Label Safety Study (Study 201)
Rimegepant is Effective for the Acute Treatment of Migraine in Subjects Who Have Discontinued or Currently Use Triptans: Results from 3 Phase 3 Clinical Trials
Rimegepant is Safe and Tolerable for the Acute Treatment of Migraine in Patients Using Preventive Migraine Medications: Results from a Long-Term Open-Label Safety Study (Study 201)
Safety and tolerability of DFN-15 (Celecoxib Oral Solution, 25 mg/mL) in the Acute Treatment of Episodic Migraine: Safety Results from Two Phase III Randomized, Double-blind, Placebo-controlled Studies
Safety and Tolerability of Galcanezumab in Patients with Chronic Cluster Headache with Up to 15-months of Galcanezumab Treatment
Safety and Tolerability of Ubrogapant for the Acute Treatment of Migraine Following Co-administration with Preventive Monoclonal Antibody Treatment
Safety and Tolerability of Ubrogapant within Various Demographic and Clinical Characteristic Subgroups
Sustained Benefits of OnabotulinumtoxinA Treatment in Chronic Migraine: Results from a PREEMPT Pooled Analysis
WITHDRAWN BY AUTHOR Tolerability of Lasmiditan in Elderly Patients with Migraine

Treatment Outcomes for Oral, Subcutaneous and Intranasal Forms of Sumatriptan: Survey Results from Migraine in America Symptoms and Treatment (MAST) Study
Ubrogepant is Effective in the Acute Treatment of Migraine with Mild Pain
Industry-initiated Research (no clinical trials)
A Comparison of Efficacy, Tolerability and Safety of Indomethacin Versus Specialized Boswellia Serrata Extract in Subjects with Confirmed Hemicrania Continua
Beyond Frequency Alone - Exploring What Meaningful Improvement Means in the Treatment of Migraine: Focus Groups in Patients and Health Care Providers
Cost-effectiveness Sequential Simulation Modeling of Fremanezumab Versus Other Therapies for Migraine Prevention from Private and Public Payer Perspectives in Canada
Does Dihydroergotamine Treat the “Whole Migraine”?
Patient Characteristics and Utilization Associated with Galcanezumab Initiation in Patients with Migraine
Seeking Care, Diagnosis, and Acute Prescription for Migraine Among Those with Headache-Related Disability: Results of the OVERCOME Study
Ubrogepant Does Not Induce Latent Sensitization in a Preclinical Model of Medication Overuse Headache
Other Headache Disorders
Calcitonin Receptor-related Peptide Inhibitors in the Treatment of Trigeminal Nerve Pain
Noninvasive Vagal Nerve Stimulation in a Pediatric Patient with Visual Snow Syndrome
Reversible Cerebral Vasoconstriction Syndrome Presenting with Symptoms of Intracranial Hypotension
Treating Red Ear Syndrome with Oxygen
Visual Snow Case Series: Review of 248 Cases with Attention to Underlying Causes or Inciting Events
Pathophysiology and Imaging of Headache Disorders
CSF Space Compliance is Predictive of Spontaneous Intracranial Hypotension

Functional Connectivity in Migraineurs with Photo-, Photo-osmophobia: Static and Dynamic Resting-state Functional Magnetic Resonance Imaging Study
WITHDRAWN BY AUTHOR Sodium Chemical Shift Imaging Reveals CSF Sodium Changes with Migraine Onset
When Pills Don't Work: Gastroparesis in Migraine
Pharmacology
Acute Care: Walk-In Headache Treatment within Neurology Outpatient Clinic
NIH HEAL Initiative Programs to Accelerate Development of Non-addictive Therapeutics for Pain: Preclinical Screening Platform for Pain and Early Phase Pain Investigation Clinical Network
Oral Candidiasis in a Migraine Patient taking Erenumab (Aimovig) and Galcanezumab (Emgality)
WITHDRAWN BY AUTHOR Petadolex, An Oral CGRP Inhibitor and Anti-inflammatory Therapeutic in Migraine Prevention
Post-traumatic Headache, TBI, and Concussion
Exploring Naturally Occurring Clinical Subgroups of Post-traumatic Headache
Measuring Impact of Activity and Concussion on Neuropathic Pain and CGRP Expression in Adolescent Rats
Randomized Controlled Trial of Prazosin for Post-traumatic Headache Prophylaxis in Veterans and Active Duty Soldiers
Treatment with OnabotulinumtoxinA versus Erenumab for Patients with Acquired/Post-traumatic Chronic Migraine
Psychological/Behavioral Issues and Treatment
A Shift in Perspective: Evidence for Abnormal Visuospatial Attentional Processes in Interictal Migraineurs & Similarities to Stroke Induced Unilateral Neglect
Clinical Outcomes for Brief Cognitive Behavioral Therapy for Youth with Headaches
Exacerbation of Headache by Lifestyle Changes Common to Pregnancy: Is Pregnancy Bound to Worsen Neurological Conditions?
Interictal Migraineurs Show Decreased Visual Spatial Attentional Response as Measured via the P300 ERP Component

<p>Program Development, Implementation and Outcomes of a Mindfulness Training Program for an Interdisciplinary Headache Team at an Academic Medical Center</p>
<p>Psychiatric Comorbidity in Children and Adolescents with New Daily Persistent Headache</p>
<p>Telehealth Occupational Therapy for Headache Disorders: A Case Series</p>
<p>The Relationship between Parent Emotional, Cognitive and Protective Responses on Functional Impairment in Youth with New Daily Persistent Headache</p>
<p>Secondary Headache</p>
<p>A Cutting Edge Therapy: Tonsilectomy for the Treatment of Probable Sleep Apnea Associated Chronic Migraine</p>
<p>Headache Induced by Deep Brain Stimulation Lead Implant for Essential Tremor</p>
<p>Narrative Review of Risk Factors and the Burden of Medication Overuse Headache on Quality-of-life and Co-morbidities</p>
<p>Spinal Cerebrospinal Fluid Leak in the context of Pars Interarticularis Fracture: A Case Series</p>
<p>Use of OnabotulinumtoxinA as Ambulatory Treatment of Brain Tumor Headaches in 2 Ambulatory Patients at MD Anderson Cancer Center: A Retrospective Chart Review</p>
<p>Industry-supported CME Program</p>
<p>Exhibit Showcase Visit sponsors in the Exhibit Showcase to learn more about new products, treatments, etc.</p>
<p>Virtual Break Room/Meditation Dawn C. Buse, PhD, FAHS, will walk attendees through relaxation instruction and techniques as we all face new professional and personal challenges during the COVID-19 pandemic.</p>